Momelotinib for Myelofibrosis: Spleen Response, Symptom Improvement and Efficacy Monitoring

　　Momelotinib is used in the treatment of myelofibrosis,particularly for patients with coexisting anemia who need both symptom control and blood-count preservation.Eligibility should follow the prescribing information and the treating physician’s assessment.In clinical studies,about 20%to 30%of patients achieved a spleen volume reduction of at least 35%from baseline during weeks 24 to 48.In patients previously treated with a JAK inhibitor,the week-24 spleen response was approximately 22%to 23%,and responses were maintained or expanded through week 48.

　　Symptom improvement usually appears earlier than measurable spleen shrinkage.Fatigue,night sweats,bone pain,early satiety and abdominal fullness may begin to ease within 1 to 2 months,while clear radiologic spleen reduction typically becomes evident around 3 months.Frequent early imaging is not necessary;reassessment at 3 to 6 months is usually more appropriate.

　　Efficacy should be evaluated together across three dimensions:

　　Spleen response:compare follow-up imaging with baseline volume,using consistent measurement methods.Palpable spleen length can support assessment but should not replace imaging.

　　Symptom response:track fatigue,night sweats,bone pain,appetite and walking tolerance.A simple symptom diary provides more useful trend information than vague impressions.

　　Hematologic response:monitor hemoglobin,transfusion requirements,platelets and neutrophils.Anemia improvement sometimes precedes visible spleen reduction.

　　A larger baseline spleen,longer disease duration or prior JAK inhibitor exposure may reduce the likelihood of dramatic spleen shrinkage.Poor adherence,infection or hepatic dysfunction can also delay response.Patients with high transfusion dependence often first show fewer transfusions and steadier hemoglobin before spleen size changes.

　　Before treatment,establish baseline spleen imaging,complete blood counts,liver and renal function,and transfusion history.Imaging is typically repeated every 3 to 6 months,while blood counts may be checked more frequently.Worsening abdominal distension should prompt abdominal girth recording and imaging review.Sudden severe left-upper-quadrant pain requires urgent evaluation to exclude splenic infarction.

　　Treatment benefit should not be judged by spleen size alone.A modest spleen response with worsening anemia,rising transfusion needs or deteriorating symptoms calls for reassessment.Conversely,meaningful clinical benefit can still exist when symptoms improve,hemoglobin stabilizes and transfusion dependence falls,even if the spleen does not fully meet response thresholds.

　　During therapy,active infection should be controlled before re-evaluating efficacy.New visual changes,persistent peripheral nerve symptoms or significant cytopenias should be reported promptly.Whether to continue,hold or adjust therapy is decided by a hematologist based on the combined clinical picture.